Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
3期
提前终止
NCT03068130
| 适应症 | Pulmonary Hypertension |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Biogen |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 261 人 |
|---|
| 干预（药物） | Bardoxolone methyl |
|---|
| 开始日期 | 2017年4月18日 |
|---|
| 完成日期 | 2020年9月30日 |
|---|
| 结果公布日 | 2023年10月12日 |
|---|
摘要
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
Long Term Safety as Measured by Incidence and Severity of Adverse Events During the Duration of the Study
From time of first dose until the final visit, up to 172 weeks · Participants
| Bardoxolone Methyl | 232 Participants |
|---|
| Bardoxolone Methyl | 89 Participants |
|---|
| Bardoxolone Methyl | 106 Participants |
|---|
| Bardoxolone Methyl | 42 Participants |
|---|
| Bardoxolone Methyl | 96 Participants |
|---|
| Bardoxolone Methyl | 94 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。